The ability of [18F]1 to bind to MDM2 expressing human tumor cells was assessed using two wild-type p53 cell lines, MCF-7 breast adenocarcinoma, and HepG2 hepatocellular carcinoma. This evidence concerns the gene TP53 and breast adenocarcinoma.